Bayer unveils plan to boost agricultural profitability amid financial challenges

Bayer has reaffirmed its commitment to revitalizing its agricultural business, despite ongoing financial pressures, as outlined in its 2024 annual report. The company met its adjusted guidance for the year but faces a challenging 2025, which CEO Bill Anderson has labeled a “pivotal year” for Bayer’s turnaround. With sales in its Crop Science division declining due to pricing pressure in the crop protection segment, the company is rolling out a comprehensive strategy to restore profitability.

Crop Science Takes Center Stage in Bayer’s Turnaround

Bayer’s Crop Science division, responsible for its agricultural business, saw a 2% decline in sales in 2024, totaling €22.26 billion (≈ $23.05 billion). The drop was mainly due to lower prices in crop protection products, driven by intense market competition. Despite these setbacks, Bayer is implementing a five-year plan aimed at boosting earnings by over €1 billion (≈ $1.04 billion) annually by 2029.

“We recognize the need to take action, our team has a plan, and they’ve got what it takes to deliver,” Anderson said at the company’s Financial News Conference in Leverkusen.

Bayer aims to achieve above-market growth in Crop Science, with expectations of €3.5 billion (approx. $3.62 billion) in additional revenue from new innovations by 2029. The company is also targeting an EBITDA margin in the mid-20s percentage by the same year.

Market Challenges and Strategic Adjustments

The agricultural industry has been grappling with falling prices and reduced planting areas, particularly in Latin America, where Bayer faced declines due to lower corn planting and price reductions in crop protection products. North America, however, provided a more stable outlook, with slight sales growth driven by increased soybean planting and higher crop protection volumes.

Bayer’s response includes a strategic review of its product portfolio, a focus on research and development, and cost efficiencies in production and commercial functions. Additionally, the company is rolling out a far-reaching cash productivity program to support its long-term profitability goals.

Financial Performance and Outlook for 2025

The company’s overall financial results reflected its ongoing challenges. Group sales for 2024 reached €46.61 billion (about $48.28 billion), with a modest 0.7% growth on a currency- and portfolio-adjusted basis. However, EBITDA before special items fell by 13.5% to €10.12 billion (≈ $10.48 billion), while net income showed a loss of €2.55 billion (≈ $2.64 billion), largely due to impairment charges in Crop Science.

For 2025, Bayer expects group sales to remain at roughly the same level as 2024, with EBITDA before special items and core earnings per share projected to decline further. Anderson emphasized that while the near-term outlook remains difficult, 2026 and beyond should bring improved performance as the company executes its turnaround strategy.

Positioning for Long-Term Growth

Despite the current financial strain, Bayer remains optimistic about its long-term agricultural prospects. The company is betting on innovation, operational efficiencies, and a disciplined financial strategy to drive sustainable growth. As competition in the global agricultural market remains fierce, Bayer’s ability to execute its five-year profitability plan will be crucial in determining its success in the years ahead.

With 2025 set to be a critical year for Bayer’s transformation, investors and industry stakeholders will closely watch how the company navigates its challenges and delivers on its promises for a stronger future in agriculture.